Plan B Decision May Offer FDA Best Political Protection Available
By
M. Nielsen Hobbs / Email the Author / “The Pink Sheet” Dec. 19, 2011, Vol. 73, No. 51
FDA / Word Count: 1045 / Article # 00111219021
Executive Summary
Assuming that sexually charged products such as Teva’s emergency contraceptive remain subject to political decision-making, the explicit heavy hand of the HHS secretary in the OTC switch ruling may be the best approach for FDA and the Rx industry, especially considering the alternatives.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.